Top

Published in:

01-12-2012 | Research Article

Clinicopathologic characteristics and outcomes of surgery of middle-third gastric cancer

Authors: Jingyu Deng, Han Liang, Rupeng Zhang, Dan Sun, Yi Pan, Li Zhang, Xishan Hao

Published in: Tumor Biology | Issue 6/2012

Abstract

Many issues of middle-third gastric cancer need to be address for obtaining preferably clinical treatment. The objective of this retrospective study was to analyze clinicopathologic characteristics and results of surgery for 113 middle-third gastric cancer patients admitted to our hospital. Retrospective cohort analyses of clinicopathologic data and postoperative prognosis of 113 middle-third gastric cancer patients who underwent curative resection between January 1997 and December 2003 were reviewed. Compared with lower-third gastric cancer patients, middle-third gastric cancer patients had significantly lower 5-year survival rate (P < 0.001) and higher recurrence rate (P < 0.001). With the Cox proportional hazards model analysis, the types of gastrectomy (hazard ratio (HR) = 0.495, P = 0.012) and ratio between metastatic and dissected lymph nodes (RML) (HR = 1.681, P < 0.001) were identified as the independent predictors of overall survival (OS) of middle-third gastric cancer patients. Besides, only RML (HR = 3.026, P < 0.001) was an independent predictor of recurrence for middle-third gastric cancer patients after surgery identified using the logistic regression analysis. The prognosis of middle-third gastric cancer was significantly worse than lower-third gastric cancer. RML was a key indicator for OS and recurrence of middle-third gastric cancer.

Ding YB, Chen GY, Xia JG, Zang XW, Yang HY, Yang L. Association of VCAM-1 Overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol. 2003;9:1409–14.PubMed

Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305–15.PubMedCrossRef

Sasako M, Saka M, Fukagawa T, Katai H, Sano T. Surgical treatment of advanced gastric cancer: japanese perspective. Dig Surg. 2007;24:101–7.PubMedCrossRef

Kulig J, Sierzega M, Kolodziejczyk P, Popiela T. Polish gastric cancer study group. Ratio of metastatic to resected lymph nodes for prediction of survival in patients with inadequately staged gastric cancer. Br J Surg. 2009;96:910–8.PubMedCrossRef

Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23:6220–32.PubMedCrossRef

Pinto-De-Sousa J, David L, Seixas M, Pimenta A. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig Surg. 2001;18:102–10.PubMedCrossRef

Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection of gastric cancer. A population-based study. Eur J Cancer. 2000;36:390–6.PubMedCrossRef

Borch K, Jönsson B, Tarpila E, et al. Changing patterns of histological type, location, stage, and outcome of surgical treatment of gastric carcinoma. Br J Surg. 2000;87:618–26.PubMedCrossRef

Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd english edition. Gastric Cancer. 1998;1:10–24.PubMedCrossRef

10.

Hundahi SA, Phillips JL, Menck HR. The national cancer data base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth Edition american joint committee on cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–32.CrossRef

11.

Harrison LE, Karpeh MS, Brennan MF. Proximal gastric cancers resected via a transabdominal only approach: results and comparisons to distal adenocarcinoma of the stomach. Ann Surg. 1997;225:678–83.PubMedCrossRef

12.

Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245:543–52.PubMedCrossRef

13.

Wang X, Wan F, Pan J, Yu GZ, Chen Y, Wang JJ. Tumor size: a non-neglectable independent prognostic factor for gastric cancer. J Surg Oncol. 2008;97:236–40.PubMedCrossRef

14.

Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol. 1994;10:12–20.PubMedCrossRef

15.

Jaehne J, Meyer HJ, Maschek H, Geerlings H, Bruns E, Pichlmayr R. Lymphadenectomy in gastric adenocarcinoma. A prospective and prognostic study. Arch Surg. 1992;127:290–4.PubMedCrossRef

16.

Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer. 2002;5:1–5.PubMedCrossRef

17.

Greene FL, Page AL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p. 99–106.

18.

Deng J, Liang H, Sun D, Pan Y. The prognostic analysis of lymph node-positive gastric cancer patients following curative resection. J Surg Res. 2010;161:47–53.PubMedCrossRef

19.

Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol. 2003;10:1077–85.PubMedCrossRef

20.

Yao JC, Tseng JF, Worah S, et al. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005;23:3094–103.PubMedCrossRef

21.

Deng J, Liang H, Wang D, Sun D, Pan Y, Liu Y. Investigation of the recurrence patterns of gastric cancer following a curative resection. Surg Today. 2011;41:210–5.PubMedCrossRef

22.

Deng JY, Liang H, Sun D, Zhan HJ, Zhang RP. Analysis of risk factors for the interval time, number and pattern of hepatic metastases from gastric cancer after radical gastrectomy. World J Gastroentrol. 2008;14:2440–7.CrossRef

23.

Stein HJ, Sendler A, Siewert JR. Site-dependent resection techniques for gastric cancer. Surg Oncol Clin N Am. 2002;11:405–14.PubMedCrossRef

24.

Clark CJ, Thirlby RC, Picozzi Jr V, Schembre DB, Cummings FP, Lin E. Current problems in surgery: gastric cancer. Curr Probl Surg. 2006;43:566–670.PubMedCrossRef

25.

Jang YJ, Park MS, Kim JH, et al. Advanced gastric cancer in the middle one-third of the stomach: should surgeons perform total gastrectomy? J Surg Oncol. 2010;101:451–6.PubMed

26.

Yokota T, Ishiyama S, Saito T, et al. Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res. 2002;22:3673–7.PubMed

27.

Sobin LH, Wittekind CH. TNM classification of malignant tumors. 6th ed. New York: Wiley; 2002.

28.

Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192:296–300.PubMedCrossRef

29.

Smith DD, Schwarz RR, Schwartz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. JCO. 2005;23:7114–24.CrossRef

30.

Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107:2143–51.PubMedCrossRef

31.

Deng JY, Liang H, Sun D, Zhan HJ, Wang XN. The appropriate cutoffs of positive lymph nodes to evaluate the prognosis of gastric cancer patients. J Surg Oncol. 2008;98:343–8.PubMedCrossRef

32.

Saito H, Fukumoto Y, Osaki T, et al. Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. J Surg Oncol. 2008;97:132–5.PubMedCrossRef

33.

Celen O, Yildirim E, Berberoglu U. Prognostic impact of positive lymph node ratio in gastric carcinoma. J Surg Oncol. 2007;96:95–101.PubMedCrossRef

34.

Persiani R, Rausei S, Biondi A, Boccia S, Cananzi F, D’Ugo D. Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer. Eur J Surg Oncol. 2008;34:519–24.PubMedCrossRef

35.

Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol. 2002;9:27–34.PubMedCrossRef

36.

Kunisaki C, Shimada H, Nomura M, et al. Clinical impact of metastatic lymph node ratio in advanced gastric cancer. Anticancer Res. 2005;25:1369–75.PubMed

37.

Bilici A, Ustaalioglu BB, Gumus M, et al. Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer? Onkologie. 2010;33:101–5.PubMedCrossRef

38.

Deng JY, Liang H, Wang DC, et al. Enhancement the prediction of postoperative survival in gastric cancer by combining the negative lymph node count with ratio between positive and examined lymph nodes. Ann Surg Oncol. 2010;17:1043–51.PubMedCrossRef

Title: Clinicopathologic characteristics and outcomes of surgery of middle-third gastric cancer
Authors: Jingyu Deng
Han Liang
Rupeng Zhang
Dan Sun
Yi Pan
Li Zhang
Xishan Hao
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0468-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Differential expression of ERCC-1 in the primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer adenocarcinoma

CD74: a potential novel target for triple-negative breast cancer

The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents

Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma

Different effects of ERβ and TROP2 expression in Chinese patients with early-stage colon cancer

Tumor-derived mesenchymal stem cells and orthotopic site increase the tumor initiation potential of putative mouse mammary cancer stem cells derived from MMTV-PyMT mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer